Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.17 USD
-0.29 (-0.12%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $237.10 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Zacks News
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Becton Dickinson (BDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
What Makes Becton Dickinson (BDX) a New Buy Stock
by Zacks Equity Research
Becton Dickinson (BDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
by Zacks Equity Research
BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?
by Moumi Mondal
Hologic's (HOLX) fundamental strength and cheaper valuation make it a great new addition to the portfolio.
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
by Zacks Equity Research
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon
by Sheraz Mian
Today's Research Daily features an earnings season update and new research reports on Broadcom (AVGO), Johnson & Johnson (JNJ) and Verizon (VZ), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Frequency Electronics, Inc. (FEIM).
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
by Zacks Equity Research
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio Now
by Zacks Equity Research
BD's (BDX) robust product portfolio raises optimism about the stock.
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
by Zacks Equity Research
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
Stock Market News for May 3, 2024
by Zacks Equity Research
U.S. stock markets closed sharply higher on Thursday.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Compared to Estimates, Becton Dickinson (BDX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Becton Dickinson (BDX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 7.09% and 0.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Zacks Equity Research
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
Sustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal second-quarter revenues.
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.